Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBT (2016 - 2026)

Ani Pharmaceuticals' EBT history spans 15 years, with the latest figure at $31.5 million for Q4 2025.

  • On a quarterly basis, EBT rose 328.74% to $31.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $95.8 million, a 531.26% increase, with the full-year FY2025 number at $95.8 million, up 531.26% from a year prior.
  • EBT hit $31.5 million in Q4 2025 for Ani Pharmaceuticals, down from $33.8 million in the prior quarter.
  • Over the last five years, EBT for ANIP hit a ceiling of $33.8 million in Q3 2025 and a floor of -$31.5 million in Q3 2024.
  • Historically, EBT has averaged -$1.3 million across 5 years, with a median of -$1.1 million in 2021.
  • Biggest five-year swings in EBT: tumbled 25997.0% in 2022 and later soared 1051.59% in 2024.
  • Tracing ANIP's EBT over 5 years: stood at -$30.9 million in 2021, then soared by 81.31% to -$5.8 million in 2022, then skyrocketed by 116.43% to $947000.0 in 2023, then tumbled by 1553.22% to -$13.8 million in 2024, then soared by 328.74% to $31.5 million in 2025.
  • Business Quant data shows EBT for ANIP at $31.5 million in Q4 2025, $33.8 million in Q3 2025, and $10.5 million in Q2 2025.